Good to See More Positive Data from NLNK for Advanced Melanoma


Newlink's general IDO pathway inhibitor Indoximod looking at least as good as Incyte's IDO inhibitor in advanced melanoma. Good news for melanoma patients. Market appreciating NLNK undervalue with stock up over 25% today. See our Seeking Alpha article from last week HERE.

Sign up to follow us on SeekingAlpha for access to future reports. Our model, hypothetical portfolio is up over 30% for the year. See our current results on our Amp Bio Research web site. Check out our LinkedIn Amp PAGE to become one of our first LinkedIn followers to assure you hear about our future reports and results.

Past performance does not predict future performance. You should do your own diligence before making any stock trades. This post is NOT investment advice.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon